News
Rituximab maintenance has a durable benefit in follicular lymphoma
At a median of 9 years of follow-up, progression-free survival was extended versus observation but there was no difference in overall survival.
News
Gene signature may help guide initial CLL treatment choice
A 17-gene expression signature may help predict which patients with IGHV-unmutated disease will benefit from frontline FCR chemoimmunotherapy or...
News
Use and costs of CRC end-of-life care differ sharply between U.S., Canada
On average, mean total costs of health care resources in the last month of life were 25% higher for SEER-Medicare patients compared with Ontario...
News
Sunitinib for mRCC: Real-world experience differs somewhat
A cohort study finds that patients treated with sunitinib as first-line therapy in routine clinical practice had poorer overall survival but also...
News
Training, alerts up the odds of discussions about genomic testing costs
A variety of physician and practice factors – some of them modifiable – increased the likelihood that oncologists discussed these often expensive...
News
Ezrin negativity predicts poor prognosis in clear cell RCC
Lack of this cytoskeleton linker protein was associated with adverse prognostic factors and independently predicted poorer disease-specific...
News
Stereotactic body radiation therapy safe, effective for moderately central NSCLC
A stereotactic body radiation therapy regimen of 50 Gy given in five fractions had limited toxicity and yielded good survival in a cohort of...
News
Lazertinib has good showing in EGFR-mutated advanced NSCLC
Data for 127 patients treated at various doses showed that 54% had a response to the new third-generation EGFR TKI. Moreover, 44% of those with...
News
Immunotherapy enables nephrectomy with good outcomes in advanced RCC
Patients able to undergo nephrectomy after receiving immune checkpoint inhibitors had favorable surgical outcomes and pathologic responses in the...
News
Nivolumab-ipilimumab nets long-term survival in advanced melanoma
An update of CheckMate 067 finds that with combination nivolumab and ipilimumab therapy, 52% of patients were alive at 5 years, and the large...
News
Cancer burden: Multiple metrics needed to clarify the big picture
A cancer’s so-called epidemiologic signature – the composite pattern of incidence, mortality, and metastatic incidence – helps sort out the...
News
AF risk is elevated after early-stage breast cancer diagnosis
The rate of AF was elevated in the first year post diagnosis and after 5 years post diagnosis, with greater elevation for women who received...
News
Mortality after breast cancer diagnosis found higher for men
Male patients had 19% higher 5-year mortality than their female counterparts even after confounders were taken into account.
News
ASCT may cure follicular lymphoma for some rituximab-naive patients
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line...
News
Meta-analysis supports hormone therapy-targeted therapy combo for advanced breast cancer
A meta-analysis of 140 trials indicated that combining hormone therapy with targeted therapy led to significantly better efficacy, reducing the...